Literature DB >> 24555506

The upstream conserved regions (UCRs) mediate homo- and hetero-oligomerization of type 4 cyclic nucleotide phosphodiesterases (PDE4s).

Moses Xie1, Brigitte Blackman1, Colleen Scheitrum1, Delphine Mika1, Elise Blanchard1, Tao Lei1, Marco Conti1, Wito Richter1.   

Abstract

PDE4s (type 4 cyclic nucleotide phosphodiesterases) are divided into long and short forms by the presence or absence of conserved N-terminal domains termed UCRs (upstream conserved regions). We have shown previously that PDE4D2, a short variant, is a monomer, whereas PDE4D3, a long variant, is a dimer. In the present study, we have determined the apparent molecular masses of various long and short PDE4 variants by size-exclusion chromatography and sucrose density-gradient centrifugation. Our results indicate that dimerization is a conserved property of all long PDE4 forms, whereas short forms are monomers. Dimerization is mediated by the UCR domains. Given their high sequence conservation, the UCR domains mediate not only homo-oligomerization, but also hetero-oligomerization of distinct PDE4 long forms as detected by co-immunoprecipitation assays and FRET microscopy. Endogenous PDE4 hetero-oligomers are, however, low in abundance compared with homo-dimers, revealing the presence of mechanisms that predispose PDE4s towards homo-oligomerization. Oligomerization is a prerequisite for the regulatory properties of the PDE4 long forms, such as their PKA (protein kinase A)-dependent activation, but is not necessary for PDE4 protein-protein interactions. As a result, individual PDE4 protomers may independently mediate protein-protein interactions, providing a mechanism whereby PDE4s contribute to the assembly of macromolecular signalling complexes.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24555506      PMCID: PMC4315173          DOI: 10.1042/BJ20131681

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  41 in total

1.  Functions of the N-terminal region of cyclic nucleotide phosphodiesterase 3 (PDE 3) isoforms.

Authors:  Y Kenan; T Murata; Y Shakur; E Degerman; V C Manganiello
Journal:  J Biol Chem       Date:  2000-04-21       Impact factor: 5.157

2.  Molecular organization of bovine rod cGMP-phosphodiesterase 6.

Authors:  J F Kameni Tcheudji; L Lebeau; N Virmaux; C G Maftei; R H Cote; C Lugnier; P Schultz
Journal:  J Mol Biol       Date:  2001-07-20       Impact factor: 5.469

3.  The cAMP-specific phosphodiesterase PDE4D3 is regulated by phosphatidic acid binding. Consequences for cAMP signaling pathway and characterization of a phosphatidic acid binding site.

Authors:  M Grange; C Sette; M Cuomo; M Conti; M Lagarde; A F Prigent; G Némoz
Journal:  J Biol Chem       Date:  2000-10-27       Impact factor: 5.157

4.  A monomeric red fluorescent protein.

Authors:  Robert E Campbell; Oded Tour; Amy E Palmer; Paul A Steinbach; Geoffrey S Baird; David A Zacharias; Roger Y Tsien
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-11       Impact factor: 11.205

5.  Activation of PDE10 and PDE11 phosphodiesterases.

Authors:  Ronald Jäger; Corina Russwurm; Frank Schwede; Hans-Gottfried Genieser; Doris Koesling; Michael Russwurm
Journal:  J Biol Chem       Date:  2011-11-21       Impact factor: 5.157

6.  In addition to the SH3 binding region, multiple regions within the N-terminal noncatalytic portion of the cAMP-specific phosphodiesterase, PDE4A5, contribute to its intracellular targeting.

Authors:  Matthew B Beard; Elaine Huston; Lachlan Campbell; Irene Gall; Ian McPhee; Stephen Yarwood; Grant Scotland; Miles D Houslay
Journal:  Cell Signal       Date:  2002-05       Impact factor: 4.315

7.  Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-alpha responses.

Authors:  S-L Catherine Jin; Marco Conti
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-28       Impact factor: 11.205

8.  Interaction between LIS1 and PDE4, and its role in cytoplasmic dynein function.

Authors:  Hannah Murdoch; Suryakiran Vadrevu; Anke Prinz; Allan J Dunlop; Enno Klussmann; Graeme B Bolger; James C Norman; Miles D Houslay
Journal:  J Cell Sci       Date:  2011-06-07       Impact factor: 5.285

9.  Long PDE4 cAMP specific phosphodiesterases are activated by protein kinase A-mediated phosphorylation of a single serine residue in Upstream Conserved Region 1 (UCR1).

Authors:  Simon J MacKenzie; George S Baillie; Ian McPhee; Carolynn MacKenzie; Rachael Seamons; Theresa McSorley; Jenni Millen; Matthew B Beard; Gino van Heeke; Miles D Houslay
Journal:  Br J Pharmacol       Date:  2002-06       Impact factor: 8.739

10.  Sub-family selective actions in the ability of Erk2 MAP kinase to phosphorylate and regulate the activity of PDE4 cyclic AMP-specific phosphodiesterases.

Authors:  G S Baillie; S J MacKenzie; I McPhee; M D Houslay
Journal:  Br J Pharmacol       Date:  2000-10       Impact factor: 8.739

View more
  13 in total

1.  The RNA-binding protein SERBP1 interacts selectively with the signaling protein RACK1.

Authors:  Graeme B Bolger
Journal:  Cell Signal       Date:  2017-03-04       Impact factor: 4.315

2.  Engineered stabilization and structural analysis of the autoinhibited conformation of PDE4.

Authors:  Peder Cedervall; Ann Aulabaugh; Kieran F Geoghegan; Thomas J McLellan; Jayvardhan Pandit
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-09       Impact factor: 11.205

3.  Ablation of PDE4B protects from Pseudomonas aeruginosa-induced acute lung injury in mice by ameliorating the cytostorm and associated hypothermia.

Authors:  Lina Abou Saleh; Abigail Boyd; Ileana V Aragon; Anna Koloteva; Domenico Spadafora; Wadad Mneimneh; Robert A Barrington; Wito Richter
Journal:  FASEB J       Date:  2021-09       Impact factor: 5.834

4.  RACK1 and β-arrestin2 attenuate dimerization of PDE4 cAMP phosphodiesterase PDE4D5.

Authors:  Graeme B Bolger
Journal:  Cell Signal       Date:  2015-08-06       Impact factor: 4.315

5.  The cAMP-phosphodiesterase 4 (PDE4) controls β-adrenoceptor- and CFTR-dependent saliva secretion in mice.

Authors:  Abigail Boyd; Ileana V Aragon; Lina Abou Saleh; Dylan Southers; Wito Richter
Journal:  Biochem J       Date:  2021-05-28       Impact factor: 3.766

6.  Dimerization of cAMP phosphodiesterase-4 (PDE4) in living cells requires interfaces located in both the UCR1 and catalytic unit domains.

Authors:  Graeme B Bolger; Allan J Dunlop; Dong Meng; Jon P Day; Enno Klussmann; George S Baillie; David R Adams; Miles D Houslay
Journal:  Cell Signal       Date:  2014-12-27       Impact factor: 4.315

7.  Phenotypic, chemical and functional characterization of cyclic nucleotide phosphodiesterase 4 (PDE4) as a potential anthelmintic drug target.

Authors:  Thavy Long; Liliana Rojo-Arreola; Da Shi; Nelly El-Sakkary; Kurt Jarnagin; Fernando Rock; Maliwan Meewan; Alberto A Rascón; Lin Lin; Katherine A Cunningham; George A Lemieux; Larissa Podust; Ruben Abagyan; Kaveh Ashrafi; James H McKerrow; Conor R Caffrey
Journal:  PLoS Negl Trop Dis       Date:  2017-07-13

Review 8.  An update of cyclic nucleotide phosphodiesterase as a target for cardiac diseases.

Authors:  Si Chen; Chen Yan
Journal:  Expert Opin Drug Discov       Date:  2020-09-21       Impact factor: 6.098

9.  Further Insights in the Binding Mode of Selective Inhibitors to Human PDE4D Enzyme Combining Docking and Molecular Dynamics.

Authors:  Pasqualina D'Ursi; Sara Guariento; Gabriele Trombetti; Alessandro Orro; Elena Cichero; Luciano Milanesi; Paola Fossa; Olga Bruno
Journal:  Mol Inform       Date:  2016-06-20       Impact factor: 3.353

10.  Altered phosphorylation, electrophysiology, and behavior on attenuation of PDE4B action in hippocampus.

Authors:  Susan L Campbell; Thomas van Groen; Inga Kadish; Lisa High Mitchell Smoot; Graeme B Bolger
Journal:  BMC Neurosci       Date:  2017-12-02       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.